The Catheters and Active Implantable CDMO Market was valued at USD 6.92 billion in 2023. The industry is projected to grow from USD 7.49 billion in 2024 to USD 18.8 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.82% during the forecast period (2024 - 2032).
The increasing strategic initiatives associated with catheters and active implantable CDMO and increased manufacturing outsourcing are driving the market growth.
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Growing initiatives are driving innovation and improving market accessibility, which is substantially fueling the growth of the global market for catheters and active implantable CDMOs. By pooling resources and experience, strategic mergers and acquisitions help businesses provide all-inclusive solutions and quicken product development. Concurrently, the use of sophisticated catheters and implantable devices is growing due to growing investments in healthcare infrastructure, particularly in emerging markets, and a growing preference for minimally invasive procedures.
For instance, in September 2023, Cirtec Medical Corp. (US), a premier provider of medical device manufacturing solutions and Resonant Link (US), a leader in wireless charging technology both partnered poised to revolutionize the future of implantable medical devices. This partnership combines Resonant Link’s cutting-edge wireless power technology with Cirtec Medical’s extensive expertise in product design, development, and manufacturing. The synergy between these two industry leaders promises to deliver superior technology, fully integrated components, and expedited time-to-market for medical device manufacturers. Thus, growing initiatives in the global catheter and active implantable CDMO sector are significantly boosting market accessibility and driving innovation. A key component of this expansion is strategic mergers and acquisitions, which allow businesses to provide all-inclusive solutions and quicken development.
Based on the service segment, the Catheters and Active Implantable CDMO Market has been segmented into Catheters, Active Implantable Devices, and Endoscopy Devices. The Catheters segment dominated the market in 2023, while the Active Implantable Devices segment is projected to be the fastest-growing segment during the forecast period, 2023–2032.
The catheters are experiencing robust growth due to several key drivers. The increasing prevalence of chronic diseases such as cardiovascular disorders, diabetes, and renal conditions necessitates the use of catheters for diagnosis and treatment. For instance, according to the IDF Diabetes Atlas (2021), 10.5% of adults aged 20 to 79 have diabetes, with nearly half unaware of the being diagnosed. According to IDF forecasts, by 2045, one in every eight persons, or roughly 783 million, will have diabetes, representing a 46% rise. Advances in technology are leading to the development of more sophisticated and patient-friendly catheter designs, which are driving market expansion. The rise in demand for active implantable catheters is driven by the increasing need for precision and reliability in medical interventions. Active implantable catheters, which may include components like sensors or miniaturized electronics for real-time monitoring, demand high levels of expertise in both device design and manufacturing processes. For instance, Zeus Industrial Products, a specialist in advanced polymer solutions, has signed an agreement to integrate CathX Medical into its operations. CathX is a medical device contract manufacturer that provides companies a single source for catheter design engineering services, fast prototyping, production, and full or sub-assemblies.
Furthermore, the rising incidence of heart failure, driven by factors such as an aging population and increasing rates of cardiovascular diseases, is propelling the demand for these innovative devices. For instance, according to UNFPA India, while India has the youngest people, the population is increasingly ageing. The current old population of 153 million (aged 60 and above) is anticipated to grow to a startling 347 million by 2050. This demographic shift is more than just a number; it is a societal transformation of unprecedented scope with far-reaching consequences. Advanced heart failure devices can significantly enhance patient outcomes by providing real-time monitoring, precise electrical therapy, and improved heart function management.
FIGURE 2: CATHETERS AND ACTIVE IMPLANTABLE CDMO MARKET SIZE, BY SERVICE SEGMENT, 2023 & 2032 (USD BILLION)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
On the basis of end user, the Catheters and Active Implantable CDMO Market is segmented into medical device OEM companies, academic and research institutes, and government agencies. The medical device OEM companies segment dominated the market in 2023 and is projected to be the fastest-growing segment during the forecast period, 2023–2032.
Medical Device Original Equipment Manufacturers (OEMs) are crucial entities in the healthcare sector, responsible for the end-to-end development and production of medical devices. These companies play a pivotal role in transforming innovative concepts into market-ready products through comprehensive services that include design, prototyping, manufacturing, and regulatory compliance. The complexity of advanced implantable devices demands specialized technological expertise and regulatory compliance, essential for navigating stringent approval processes. Rising chronic disease rates and the shift toward minimally invasive solutions are increasing device demand. OEMs seek cost-effective, scalable manufacturing solutions and flexible design capabilities from CDMOs to meet these needs. Additionally, advancements in materials and global market expansion necessitate partnerships with CDMOs that offer innovative manufacturing techniques and can manage international standards. For instance, In January 2024, Germany-based Sanner Group, a global healthcare packaging manufacturer and medical device contract development and manufacturing organization (CDMO), acquired Springboard, a design and development firm specializing in medical devices for regulated markets. The acquisition aligns with the company's goal of developing a portfolio of "world-leading services for customers across the drug-delivery, diagnostic, and medtech device sectors." Springboard's comprehensive skills will significantly strengthen Sanner Group's in-house medical device development services, and the establishment of a new Design Center of Excellence in the UK.
Academic and research institutes are pivotal to the advancement of the medical device industry, serving as hubs of innovation and development. These institutions drive technological progress by conducting cutting-edge research, developing novel medical devices, and testing new concepts through rigorous clinical trials and laboratory evaluations. Additionally, Government agencies as end users of Contract Development and Manufacturing Organizations (CDMOs) specializing in active implantable medical devices engage in highly specialized partnerships to ensure the development and production of advanced, life-sustaining technologies.
Based on region, the Catheters and Active Implantable CDMO Market has been segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America accounted for the largest market share in 2023 and is anticipated to reach during the forecast period. However, Asia-Pacific is projected to grow at the highest CAGR during the forecast period.
The Active Implantable CDMO market in North America is characterized by robust growth driven by technological advancements, a supportive regulatory environment, and increasing healthcare needs. Moreover, sophisticated healthcare infrastructure and substantial investment in research and development, enabling the creation of cutting-edge implantable devices drives the market. Furthermore, opportunities for expansion into emerging markets, the rise of personalized medicine, and the demand for minimally invasive solutions present avenues for growth. Moreover, strategic partnership and collaborations are fueling the demand for active implantable in North America. For instance, in December 2022, Veranex acquired Fusion Biotec, a company based in Orange, California that specializes in the design and engineering of complicated electromechanical diagnostic and medical equipment. The agreement brings together Veranex's infrastructure and quick development skills with Fusion's rapid concept-to-production capabilities, improving their focus on expediting diagnostic and medical technology solutions for regulatory and commercial success.
The Americas region is followed by Europe, which is further segmented into the Germany, France, UK, Italy, Spain, and Rest of the Europe. The Active Implantable CDMO market in Europe is marked by significant growth potential driven by technological advancements, and rising healthcare needs. Technological advancements in implantable devices—such as next-generation cardiac pacemakers, neurostimulators, and insulin pumps—are propelling demand for specialized manufacturing expertise. The increasing prevalence of chronic diseases, driven by an aging population, further amplifies the need for sophisticated, high-quality implantable solutions. For instance, according to European Commission, On January 1, 2023, the EU population was anticipated to be 448.8 million individuals, with more than one-fifth (21.3%) of those aged 65 years or older. Opportunities include expanding into emerging regional markets, focusing on personalized medicine, and developing minimally invasive technologies.
Asia-Pacific is expected to witness significant growth and is projected to be the fastest growing region over the forecast period and experiencing robust growth driven by several key factors Rapid advancements in medical technology and increasing investments in healthcare infrastructure across countries like China, India, and Japan are fueling demand for sophisticated implantable devices. The rising prevalence of chronic diseases, diabetes and an aging population further drive the need for innovative solutions. For instance, according to National Institutes of Health (NIH), in Dec 2021, Diabetes accounts for approximately 80% of the worldwide disease burden, with Asia accounting for 60% of diabetics. Asia also has six of the top ten countries with the highest diabetes prevalence. Additionally, the region’s growing focus on enhancing healthcare access and affordability creates significant opportunities for CDMOs. Favorable regulatory environments in emerging markets and supportive government initiatives also contribute to market expansion. Furthermore, strategic partnerships and collaborations with local medical device manufacturers enhance the ability of CDMOs to scale operations and meet the diverse needs of the regional market.
FIGURE 3: CATHETERS AND ACTIVE IMPLANTABLE CDMO MARKET BY REGION 2023 & 2032 (USD BILLION)
The Catheters and Active Implantable CDMO Market is characterized by the presence of many global, regional, and local vendors. The market is highly competitive, with all the players competing to gain maximum market share. Intense competition, frequent changes in government policies, and regulations are key factors that impact market growth. The vendors compete based on cost, product quality, reliability, and aftermarket services.
Product launch and approvals were also observed to expand the company's product portfolio. The growth of prominent industry players is dependent on various factors, such as market conditions, product differentiation and innovation, and pricing strategies. It is also projected that increasing investment by the biopharmaceutical industry associated with Medical Devices like Catheters and Active Implantable Devices will boost the market's growth in the upcoming future.
Major players in the Catheters and Active Implantable CDMO Market, including Integer Holding Corporation, Heraeus Group, Cirtec, Freudenberg Medical, Veranex, and others are making investments in R&D activities to boost market demand.
Freudenberg Medical is a global Contract Manufacturing Organization (CMO) and Contract Development and Manufacturing Organization (CDMO) with 11 manufacturing sites around the world. They are global specialists in medical technology with over 30 years of experience in medical devices and pharmaceutical applications. They support a wide range of medical and life science customers globally, enhancing its ability to cater to diverse regional and market-specific needs.
In February 2021, Freudenberg Medical has opened a second production facility in Costa Rica. This expansion supports their strategy of being close to customers, offering efficient solutions throughout the device lifecycle, including large-scale, cost-effective manufacturing capabilities. Initial manufacturing operations will begin in early 2025.
February 2024: Freudenberg Medical has opened a second production facility in Costa Rica. This expansion supports their strategy of being close to customers, offering efficient solutions throughout the device lifecycle, including large-scale, cost-effective manufacturing capabilities. Initial manufacturing operations will begin in early 2025.
September 2023: Biomerics announced the completion of a 100,000-square-foot expansion of their facilities in Brooklyn Park, Minnesota, increasing the facility's overall size to 170,000 square feet. Due to rising demand, this investment benefits clients by integrating numerous facilities under one roof and extending Biomerics' engineering Centers of Excellence for Complex Extrusions, Laser Processing, Advanced Catheters & Steerables, and final assembly processes.
August 2023: Second Source Medical (SSM), a Medeologix company, has officially launched its Advanced Catheter Development Center, featuring cutting-edge technology and engineering expertise.
October 2022: Veranex has announced the acquisition of a full-service ecosystem of medical device consultancy companies, enhancing its offerings in regulatory and clinical affairs, quality assurance, and biocompatibility for medical and IVD devices.
Catheters
Active Implantable Devices
North America
Europe
Asia-Pacific
Rest of the World
Middle East & Africa
South America
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 6.92 billion |
| Market Size 2024 | USD 7.49 billion |
| Market Size 2032 | USD 18.8 billion |
| Compound Annual Growth Rate (CAGR) | 10.82% (2024-2032) |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2019 to 2022 |
| Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends. |
| Segments Covered | Service Category, End Users, and Region. |
| Key Companies Profiled | Integer Holdings Corporation (US), Cirtec (US), Biomerics (US), Switchback Medical (US), Velentium LLC (US), Heraeus Group (Germany), Zeus Company LLC (US), Veranex (US), Freudenberg Medical (US), Medeologix (Taiwan) |
| Key Market Opportunities | · Growing geriatric population across the globe. · Facility expansion by contract development manufacturing organization. |
| Key Market Dynamics | · Increasing strategic initiatives associated with catheters and active implantable CDMO. · Increased outsourcing of manufacturing. |
Frequently Asked Questions (FAQ) :
The Global Catheters and Active Implantable CDMO Market is anticipated to reach 18.8 billion at a CAGR of 10.82% during the forecast period of 2023-2032.
The Global Catheters and Active Implantable CDMO Market is expected to grow at a 10.82% CAGR during the forecast period from 2023 to 2032.
The North America region market is estimated to hold the largest market share in the Global Catheters and Active Implantable CDMO Market.
The key players include Integer Holdings Corporation (US), Cirtec (US), Biomerics (US), Switchback Medical (US), Velentium LLC (US), Heraeus Group (Germany), Zeus Company LLC (US), Veranex (US), Freudenberg Medical (US), Medeologix (Taiwan).
Catheters devices segment dominated the market in 2023.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
